Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Fuji Submits NDI Notification for Astaxanthin - Nutraceuticals World
Market Updates

Fuji Submits NDI Notification for Astaxanthin

Fuji Health Science, Burlington, NJ, has submitted a New Dietary Ingredient Notification (NDIN) to FDA for AstaREAL astaxanthin at 12 mg per day. In connection with the notification, the company received a no-objection letter from FDA. Fuji Health Science said the purpose of the NDIN was to support the dietary supplement industry’s widening range of potential astaxanthin users.

“With this successful NDIN, Fuji reaffirms once again its commitment to quality and safety as its number one priority,” said Charles DePrince, president of Fuji Health Science. “Also, as earlier testament to this, AstaREAL still remains the only astaxanthin that has successfully petitioned a notification to the FDA for GRAS status also receiving a no-objection letter back in January 2010 for that as well.”

The astaxanthin market is finally reaching maturity, according to Joe Kuncewitch, national sales manager for Fuji. “Up until this past year it was a specialty ingredient carried only by select customers, but astaxanthin has now gone mainstream, finding itself in mass market. The spark that ignited the astaxanthin explosion was Dr. Oz, introducing astaxanthin on his TV show last year. A year later we continue to see market expansion.” 

Add us as a preferred source on Google

Get the latest Nutraceuticals World news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Nutraceuticals World Newsletters